Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Nov 14;308(18):1881-8.
doi: 10.1001/jama.2012.12807.

Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas

Affiliations
Comparative Study

Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas

Asgeir S Jakola et al. JAMA. .

Abstract

Context: There are no controlled studies on surgical treatment of diffuse low-grade gliomas (LGGs), and management is controversial.

Objective: To examine survival in population-based parallel cohorts of LGGs from 2 Norwegian university hospitals with different surgical treatment strategies.

Design, setting, and patients: Both neurosurgical departments are exclusive providers in adjacent geographical regions with regional referral practices. In hospital A diagnostic biopsies followed by a "wait and scan" approach has been favored (biopsy and watchful waiting), while early resections have been advocated in hospital B (early resection). Thus, the treatment strategy in individual patients has been highly dependent on the patient's residential address. Histopathology specimens from all adult patients diagnosed with LGG from 1998 through 2009 underwent a blinded histopathological review to ensure uniform classification and inclusion. Follow-up ended April 11, 2011. There were 153 patients (66 from the center favoring biopsy and watchful waiting and 87 from the center favoring early resection) with diffuse LGGs included.

Main outcome measure: The prespecified primary end point was overall survival based on regional comparisons without adjusting for administered treatment. Results Initial biopsy alone was carried out in 47 (71%) patients served by the center favoring biopsy and watchful waiting and in 12 (14%) patients served by the center favoring early resection (P < .001). Median follow-up was 7.0 years (interquartile range, 4.5-10.9) at the center favoring biopsy and watchful waiting and 7.1 years (interquartile range, 4.2-9.9) at the center favoring early resection (P=.95). The 2 groups were comparable with respect to baseline parameters. Overall survival was significantly better with early surgical resection (P=.01). Median survival was 5.9 years (95% CI, 4.5-7.3) with the approach favoring biopsy only while median survival was not reached with the approach favoring early resection. Estimated 5-year survival was 60% (95% CI, 48%-72%) and 74% (95% CI, 64%-84%) for biopsy and watchful waiting and early resection, respectively. In an adjusted multivariable analysis the relative hazard ratio was 1.8 (95% CI, 1.1-2.9, P=.03) when treated at the center favoring biopsy and watchful waiting.

Conclusions: For patients in Norway with LGG, treatment at a center that favored early surgical resection was associated with better overall survival than treatment at a center that favored biopsy and watchful waiting. This survival benefit remained after adjusting for validated prognostic factors.

PubMed Disclaimer

Comment in

Similar articles

Cited by

  • Survival and low-grade glioma: the emergence of genetic information.
    Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Claus EB, et al. Neurosurg Focus. 2015 Jan;38(1):E6. doi: 10.3171/2014.10.FOCUS12367. Neurosurg Focus. 2015. PMID: 25552286 Free PMC article.
  • Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
    Cancer Genome Atlas Research Network; Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fenn… See abstract for full author list ➔ Cancer Genome Atlas Research Network, et al. N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10. N Engl J Med. 2015. PMID: 26061751 Free PMC article.
  • Changing the clinical course of glioma patients by preoperative motor mapping with navigated transcranial magnetic brain stimulation.
    Krieg SM, Sollmann N, Obermueller T, Sabih J, Bulubas L, Negwer C, Moser T, Droese D, Boeckh-Behrens T, Ringel F, Meyer B. Krieg SM, et al. BMC Cancer. 2015 Apr 8;15:231. doi: 10.1186/s12885-015-1258-1. BMC Cancer. 2015. PMID: 25884404 Free PMC article.
  • Observation after surgery for low grade glioma: long-term outcome in the light of the 2016 WHO classification.
    Jansen E, Hamisch C, Ruess D, Heiland DH, Goldbrunner R, Ruge MI, Schnell O, Grau SJ. Jansen E, et al. J Neurooncol. 2019 Dec;145(3):501-507. doi: 10.1007/s11060-019-03316-7. Epub 2019 Oct 16. J Neurooncol. 2019. PMID: 31621043
  • Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.
    Hafazalla K, Sahgal A, Jaja B, Perry JR, Das S. Hafazalla K, et al. Oncotarget. 2018 Sep 14;9(72):33623-33633. doi: 10.18632/oncotarget.25890. eCollection 2018 Sep 14. Oncotarget. 2018. PMID: 30263090 Free PMC article.

Publication types